RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults Also known as temporal arteritis, GCA is the most… Read More
VANCOUVER, BC – Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, shared key findings from its latest mRNA-LNP therapeutic research during the 2025 World Vaccine Congress, held… Read More
Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies VANCOUVER, BC – AbCellera (Nasdaq: ABCL) announced new… Read More
Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in… Read More
RESEARCH TRIANGLE PARK, NC – IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced that Marie… Read More
